Menu Search
Equities

Amicus Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
0HF9:LSE

Amicus Therapeutics Inc

Actions
  • Price (USD)14.28
  • Today's Change-0.009 / -0.06%
  • Shares traded1.08k
  • 1 Year change+46.63%
  • Beta0.4282
Data delayed at least 20 minutes, as of Feb 06 2026 16:46 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.

  • Revenue in USD (TTM)598.70m
  • Net income in USD-14.06m
  • Incorporated2002
  • Employees499.00
  • Location
    Amicus Therapeutics Inc47 Hulfish StreetPRINCETON 08542United StatesUSA
  • Phone+1 (609) 662-2000
  • Fax+1 (609) 662-2001
  • Websitehttps://www.amicusrx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.